Therapeutic Algorithm Guided by Sequential 11C-Choline PET/CT in a Patient With Metastatic Castration-Resistant Prostate Cancer.
作者： JR Garcia Garzon , Pere Bassa , Marina Soler , Merce Moragas , Elena Llinares
DOI: 10.1097/RLU.0000000000000758
关键词: Cabazitaxel 、 Oncology 、 Nuclear medicine 、 Prostate cancer 、 Therapeutic algorithm 、 Antiandrogen Therapy 、 Docetaxel 、 Medicine 、 Internal medicine 、 Androgen 、 Castration resistant 、 Positron emission tomography
摘要: Antiandrogen therapy alone or combined with radical is the first choice in diagnosis and recurrence of patients metastatic prostate cancer. However, on androgen deprivation frequently show treatment resistance. In recent years, new treatments for castration-resistant cancer have been developed. Clinical studies docetaxel shown its usefulness first-line therapy, different therapeutic algorithms second-line drugs like abiraterone cabazitaxel also proposed. Sequential metabolic study PET/CT imaging ¹¹C-choline may be important assessing right moment administration each one options.
sci-hub.st 参考文章(8)
Orazio Caffo, Francesca Maines, Davide Donner, Antonello Veccia, Franca Chierichetti, Enzo Galligioni, Impact of Enzalutamide Administration on Primary Prostate Cancer Volume: A Metabolic Evaluation by Choline Positron Emission Tomography in Castration-Resistant Prostate Cancer Patients Clinical Genitourinary Cancer. ,vol. 12, pp. 312- 316 ,(2014) , 10.1016/J.CLGC.2014.03.004
C J Ryan, W Peng, T Kheoh, E Welkowsky, C M Haqq, D W Chandler, H I Scher, A Molina, Androgen dynamics and serum PSA in patients treated with abiraterone acetate Prostate Cancer and Prostatic Diseases. ,vol. 17, pp. 192- 198 ,(2014) , 10.1038/PCAN.2014.8
HSIANG-YING LEE, WEN-JENG WU, CHUN-HSIUNG HUANG, YII-HER CHOU, CHUN-NUNG HUANG, YUNG-CHIN LEE, KAI-FU YANG, MEI-HUI LEE, SHU-PIN HUANG, Clinical predictor of survival following docetaxel‑based chemotherapy Oncology Letters. ,vol. 8, pp. 1788- 1792 ,(2014) , 10.3892/OL.2014.2349
Eva Gupta, Troy Guthrie, Winston Tan, Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC) BMC Urology. ,vol. 14, pp. 55- 55 ,(2014) , 10.1186/1471-2490-14-55
A. Irelli, G. Bruera, K. Cannita, E. Palluzzi, G. L. Gravina, C. Festuccia, C. Ficorella, E. Ricevuto, Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer. BioMed Research International. ,vol. 2014, pp. 909623- 909623 ,(2014) , 10.1155/2014/909623
D. Andrew Loblaw, Katherine S. Virgo, Robert Nam, Mark R. Somerfield, Edgar Ben-Josef, David S. Mendelson, Richard Middleton, Stewart A. Sharp, Thomas J. Smith, James Talcott, Maryellen Taplin, Nicholas J. Vogelzang, James L. Wade, Charles L. Bennett, Howard I. Scher, Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline Journal of Clinical Oncology. ,vol. 25, pp. 1596- 1605 ,(2007) , 10.1200/JCO.2006.10.1949
Sergio Bracarda, Michele Sisani, Francesca Marrocolo, Alketa Hamzaj, Sabrina Del Buono, Amelia Altavilla, Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view. Expert Review of Anticancer Therapy. ,vol. 14, pp. 1283- 1294 ,(2014) , 10.1586/14737140.2014.965686
Leonard G Gomella, Daniel P Petrylak, Bobby Shayegan, Current management of advanced and castration resistant prostate cancer. Canadian Journal of Urology. ,vol. 21, pp. 1- 6 ,(2014)